BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

819 results

Results per page: 10 20 30

Dear Doctor Letter (Rote-Hand-Brief) on VOLIBRIS® (ambrisentan): New Contraindication PDF, 1MB, File is accessible Date: 09. July 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: ambrisentan

VOLIBRIS® (ambrisentan) must not be given to patients with idiopathic pulmonary fibrosis (IPF).

Rote-Hand-Brief on Volibris® PDF, 1MB, File is accessible Date: 06. July 2012 Topics: Pharmakovigilanz Type: Download

Active substance: ambrisentan

Anapen® solution for injection 300 μg adrenaline in 0.3 ml solution for injection, pre-filled syringe / Anapen® Junior 150 μg adrenaline in 0.3 ml solution for injection, pre-filled syringe by Lincoln Medical Limited (adrenaline): Recall of all batches on patient level PDF, 103KB, File is accessible Date: 06. June 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: adrenaline

Lincoln Medical Limited is recalling all unexpired units of the a.m. medicinal product because of the risk of failure to deliver the adrenaline solution in an anaphylactic emergency situation.

Carboplatin: Formation of insoluble particles in medicinal products containing carboplatin Date: 04. June 2012 Topics: Pharmakovigilanz Type: Risk information

Active substance: carboplatin

Further measures have been introduced due to the persisting occurrence of insoluble particles in numerous medicinal products containing carboplatin and because of a possible shortage of medicinal products containing carboplatin.

Adenuric® (febuxostat): Risk of hypersensitivity reactions including Stevens-Johnson Syndrome and acute anaphylactic reaction/shock PDF, 113KB, File is accessible Date: 22. May 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: febuxostat

Serious hypersensitivity reactions have been reported under treatment with Adenuric®. In most of the cases these reactions occurred during the first month of treatment with febuxostat.

Rote-Hand-Brief on Adenuric® PDF, 113KB, File is accessible Date: 21. May 2012 Topics: Pharmakovigilanz Type: Download

Active substance: febuxostat

Carboplatin: Formation of insoluble particles in medicinal products containing carboplatin Date: 16. May 2012 Topics: Pharmakovigilanz Type: Risk information

Active substance: carboplatin

Extensive measures for risk minimisation have been introduced because of the occurrence of insoluble particles in numerous medicinal products from several pharmaceutical entrepreneurs that contain carboplatin.

Information Letter on Protopic® PDF, 625KB, File is accessible Date: 11. May 2012 Topics: Pharmakovigilanz Type: Download

Active substance: tacrolimus

Information Letter on Protopic® (tacrolimus): Recommendations for the correct use PDF, 625KB, File is accessible Date: 11. May 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: tacrolimus

Important recommendations for the correct use of Protopic® (0.03% and 0.1%) Ointment in order to minimise risks, especially when treating children.

Information Letter on Viaspan® PDF, 168KB, File is accessible Date: 10. May 2012 Topics: Pharmakovigilanz Type: Download

Organ preservation solution